Table 3. Comparison of clinical and laboratory results at each timepoint using generalized estimating equations analysis.
| Result | Group 1 | Group 2 | Difference | ||
|---|---|---|---|---|---|
| p-value | Ratio (95% CI) | ||||
| EASI score | |||||
| T0 | 26.58 (23.10–30.27) | 27.66 (25.28–30.57) | 0.588 | 0.96 (0.81–1.13) | |
| T1 | 5.58 (4.53–6.89) | 3.56 (2.41–5.26) | 0.045 | 1.57 (1.01–2.44) | |
| T2 | 3.46 (2.64–4.53) | 2.05 (1.36–3.06) | 0.038 | 1.68 (1.03–2.75) | |
| T3 | 2.16 (1.45–3.25) | 1.79 (0.92–3.42) | 0.615 | 1.22 (0.57–2.62) | |
| IgE | |||||
| T0 | 2,591.52 (1,510.20–4,491.76) | 1,603.59 (445.86–5,825.50) | 0.5 | 1.62 (0.40–6.54) | |
| T1 | 1,211.97 (317.35–4,628.55) | 607.89 (149.90–2,489.91) | 0.492 | 1.98 (0.28–13.88) | |
| T2 | 720.54 (139.77–3,751.83) | 237.46 (83.93–671.83) | 0.266 | 3.03 (0.43–21.37) | |
| T3 | 518.01 (172.43–1,571.84) | 146.94 (56.26–383.75) | 0.095 | 3.53 (0.80–15.53) | |
| Eosinophil count | |||||
| T0 | 487.85 (333.62–706.27) | 742.48 (445.86–1,248.88) | 0.189 | 0.65 (0.35–1.23) | |
| T1 | 244.69 (152.93–391.51) | 347.23 (214.86–555.57) | 0.313 | 0.71 (0.36–1.38) | |
| T2 | 376.15 (295.89–478.19) | 314.19 (219.20–450.34) | 0.416 | 1.20 (0.78–1.85) | |
| T3 | 183.09 (130.32–254.68) | 273.14 (159.17–473.43) | 0.211 | 0.67 (0.35–1.26) | |
Values are presented as mean (interquartile range).
Mean estimated values are demonstrated, accompanied by 95% CIs. The logistic regression estimation with generalized estimating equations was used for analysis to account for the interaction effect between time and tapering.
CI: confidence interval, EASI: Eczema Area and Severity Index, IgE: immunoglobulin E.